Assessing Medpace Holdings (MEDP) Valuation After Securities Class Actions And Fourth Quarter 2025 Fallout

Simply Wall St.05-25

AdvertisementWhy a wave of lawsuits has put Medpace Holdings (MEDP) in the spotlight Recent securities class actions against Medpace Holdings (MEDP) allege false and misleading statements about book ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638075307?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-05-25 04:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638075307","market":"us","top_or_hot":-1,"title":"Assessing Medpace Holdings (MEDP) Valuation After Securities Class Actions And Fourth Quarter 2025 Fallout","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy a wave of lawsuits has put Medpace Holdings (MEDP) in the spotlight Recent securities class actions against Medpace Holdings (MEDP) allege false and misleading statements about book ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/assessing-medpace-holdings-medp-valuation-after-securities-c\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Medpace Holdings (MEDP) Valuation After Securities Class Actions And Fourth Quarter 2025 Fallout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Medpace Holdings (MEDP) Valuation After Securities Class Actions And Fourth Quarter 2025 Fallout\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-25 04:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/assessing-medpace-holdings-medp-valuation-after-securities-c><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy a wave of lawsuits has put Medpace Holdings (MEDP) in the spotlight Recent securities class actions against Medpace Holdings (MEDP) allege false and misleading statements about book ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/assessing-medpace-holdings-medp-valuation-after-securities-c\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MEDP","symbol_name":"Medpace Holdings Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/assessing-medpace-holdings-medp-valuation-after-securities-c","article_id":"2638075307","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/assessing-medpace-holdings-medp-valuation-after-securities-c","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2638075307","pubTimestamp":1779654115,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why a wave of lawsuits has put Medpace Holdings (MEDP) in the spotlight\nRecent securities class actions against Medpace Holdings (MEDP) allege false and misleading statements about book to bill guidance, backlog cancellations, and business prospects, with investors pointing to fourth quarter 2025 results as the turning point.\nSee our latest analysis for Medpace Holdings.\nMedpace’s share price has recently been volatile, with a 7 day share price return of 4.22% and a 30 day share price return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MEDP":"Medpace Holdings Inc.","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4121":"生命科学工具和服务","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4588":"碎股","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4585":"ETF&股票定投概念"},"translate_title":"评估证券集体诉讼后Medpace Holdings(MEDP)的估值以及2025年第四季度的影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDP":1.5},"content_text":"AdvertisementWhy a wave of lawsuits has put Medpace Holdings (MEDP) in the spotlight Recent securities class actions against Medpace Holdings (MEDP) allege false and misleading statements about book to bill guidance, backlog cancellations, and business prospects, with investors pointing to fourth quarter 2025 results as the turning point. See our latest analysis for Medpace Holdings. Medpace’s share price has recently been volatile, with a 7 day share price return of 4.22% and a 30 day share price return of 5.42%. However, year to date the share price is down 24.21%, even as the 1 year total shareholder return sits at 46.77%, suggesting momentum has cooled after a stronger run over recent years. If these legal headlines have you reassessing your exposure to healthcare, it might be worth widening your search with a curated set of 34 healthcare AI stocks With Medpace trading close to the average analyst price target yet flagged with an intrinsic discount of about 32%, investors are left with a key question: is the recent pullback a genuine opportunity, or is the stock already pricing in future growth? Most Popular Narrative: 13.5% Undervalued With Medpace last closing at $432.80 against a widely followed fair value estimate of about $500.08, the core question is how the underlying earnings and cash flow story supports that gap.  The rapid revenue acceleration in 2025 is heavily influenced by a therapeutic mix shift toward faster-burning studies (such as metabolic trials) with higher reimbursable costs, increasing \"pass-through\" revenue that is less margin-accretive. This could result in lower underlying revenue and EBITDA growth once this project mix normalizes. Funding for many clients, especially small biotech, remains fragile, with low cancellations having driven recent upside. If the improved funding environment or lower cancellations were to reverse (as seen in previous quarters), revenue and earnings growth could sharply decelerate, indicating that the current growth levels may not be sustainable.  Read the complete narrative. Want to understand why this valuation still lands above the current share price? The narrative rests on a specific earnings glide path, firm margin assumptions, and a future P/E that implies a tighter gap to sector leaders. Curious which revenue profile and profitability mix underpin that fair value and how buybacks fit into the equation? Result: Fair Value of $500.08 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story can change quickly if biotech funding weakens again or faster burning contracts roll off sooner than expected, pressuring backlog and earnings visibility. Find out about the key risks to this Medpace Holdings narrative. Next Steps Given this mixed sentiment, do not wait for the next headline to make up your mind. Review the upside factors yourself with the 3 key rewards Looking for more investment ideas? If you stop with Medpace, you risk missing other stocks that might suit your goals, so take a few minutes to scan a wider opportunity set.  Spot potential bargains quickly by checking out 49 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet. Prioritize resilience by reviewing 67 resilient stocks with low risk scores that score well on financial strength and business stability. Get ahead of the crowd by using the screener containing 21 high quality undiscovered gems to surface underfollowed stocks with solid fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638075307","isCrawlerRequest":true}